Abstract
Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, which were developed more than 40 years ago and present important efficacy and safety limitations. Drug repositioning (i.e. finding second or further therapeutic indications for known drugs) has raised considerable interest within the international drug development community. There are many explanations to the current interest on drug repositioning including the possibility to partially circumvent clinical trials and the consequent saving in time and resources. It has been suggested as a particular attractive approach for the development of novel therapeutics for neglected diseases, which are usually driven by public or non-profit organizations. Here we review current computer-guided approaches to drug repositioning and reports on drug repositioning stories oriented to Chagas disease, with a focus on computer-guided drug repositioning campaigns.
Keywords: Chagas disease, computer-guided drug repositioning, drug repositioning, drug repurposing, neglected diseases, indication expansion, high-throughput drug repurposing.
Mini-Reviews in Medicinal Chemistry
Title:High-throughput Drug Repositioning for the Discovery of New Treatments for Chagas Disease
Volume: 15 Issue: 3
Author(s): Carolina L. Bellera, Maria L. Sbaraglini, Dario E. Balcazar, Laura Fraccaroli, M. Cristina Vanrell, A. Florencia Casassa, Carlos A. Labriola, Patricia S. Romano, Carolina Carrillo and Alan Talevi
Affiliation:
Keywords: Chagas disease, computer-guided drug repositioning, drug repositioning, drug repurposing, neglected diseases, indication expansion, high-throughput drug repurposing.
Abstract: Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, which were developed more than 40 years ago and present important efficacy and safety limitations. Drug repositioning (i.e. finding second or further therapeutic indications for known drugs) has raised considerable interest within the international drug development community. There are many explanations to the current interest on drug repositioning including the possibility to partially circumvent clinical trials and the consequent saving in time and resources. It has been suggested as a particular attractive approach for the development of novel therapeutics for neglected diseases, which are usually driven by public or non-profit organizations. Here we review current computer-guided approaches to drug repositioning and reports on drug repositioning stories oriented to Chagas disease, with a focus on computer-guided drug repositioning campaigns.
Export Options
About this article
Cite this article as:
Bellera L. Carolina, Sbaraglini L. Maria, Balcazar E. Dario, Fraccaroli Laura, Vanrell Cristina M., Casassa Florencia A., Labriola A. Carlos, Romano S. Patricia, Carrillo Carolina and Talevi Alan, High-throughput Drug Repositioning for the Discovery of New Treatments for Chagas Disease, Mini-Reviews in Medicinal Chemistry 2015; 15(3) . https://dx.doi.org/10.2174/138955751503150312120208
DOI https://dx.doi.org/10.2174/138955751503150312120208 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins
Current Gene Therapy The Uses of Dimedone for the Synthesis of Thiophene, Thiazole and Annulated Derivatives with Antitumor, Pim-1 Kinase Inhibitions, PAINS Evaluations and Molecular Docking
Anti-Cancer Agents in Medicinal Chemistry Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry TTR Fibril Formation Inhibitors: Is there a SAR?
Current Medicinal Chemistry Therapeutic Potential of Naturally Occurring Lignans as Anticancer Agents
Current Topics in Medicinal Chemistry Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Development of Phytoestrogens and Derivatives: An Update of the Promising Perspectives in the Prevention of Postmenopausal Diseases
Mini-Reviews in Medicinal Chemistry Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Engeletin in Medicine: Therapeutic Benefit Through Scientific Data Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis and Activity Against Trypanosoma cruzi of Azaheterocyclic Analogs of Megazol
Medicinal Chemistry Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Virtual Screening and Its Integration with Modern Drug Design Technologies
Current Medicinal Chemistry Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I)
Current Pharmaceutical Design Classification of Active and Weakly Active ST Inhibitors of HIV-1 Integrase Using a Support Vector Machine
Combinatorial Chemistry & High Throughput Screening Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization
Current Organic Chemistry Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands
Drug Design Reviews - Online (Discontinued) Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents
Current Topics in Medicinal Chemistry Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Current Pharmaceutical Design Analysing the Output from Primary Screening
Combinatorial Chemistry & High Throughput Screening